To appraise the clinical and cost-effectiveness of Nivolumab in combination with relatlimab within its marketing authorisation for melanoma
Following on from information provided to NICE by the company in November 2020 the appraisal of Relatlimab with nivolumab for treating advanced malignant melanoma after immunotherapy in people over 12 [ID1612] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1612
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 20 December 2022 | Discontinued. Following on from information provided to NICE by the company in November 2020 the appraisal of Relatlimab with nivolumab for treating advanced malignant melanoma after immunotherapy in people over 12 [ID1612] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 10 December 2020 | Note added to the project documents |
| 08 May 2019 | In progress. Referred 17 October 2018 |
For further information on our processes and methods, please see our CHTE processes and methods manual